Mar Vista Investment Partners LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mar Vista Investment Partners LLC reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 16.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 184,786 shares of the company's stock after selling 37,249 shares during the period. Johnson & Johnson makes up 2.5% of Mar Vista Investment Partners LLC's portfolio, making the stock its 22nd biggest position. Mar Vista Investment Partners LLC's holdings in Johnson & Johnson were worth $30,645,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of JNJ. Norges Bank purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $4,390,037,000. GAMMA Investing LLC increased its holdings in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock worth $1,149,536,000 after buying an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.5%

JNJ stock opened at $156.87 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market cap of $377.44 billion, a P/E ratio of 17.45, a PEG ratio of 2.15 and a beta of 0.41. The business's 50-day moving average price is $153.75 and its 200-day moving average price is $154.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. Johnson & Johnson's payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research analyst reports. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a report on Thursday. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Raymond James Financial cut their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Finally, Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.